Astria Therapeutics, Inc.

This Phase 3 trial tests whether navenibart, a drug given as a shot under the skin, can prevent attacks in people with hereditary angioedema (HAE). About 145 adults and teens with HAE type 1 or 2 will receive either navenibart or a placebo for 6 months. The main goal is to see if…

This Phase 3 trial tests the long-term safety and effectiveness of navenibart, an injectable drug, in 145 adults and teens with hereditary angioedema (HAE) who were in a previous study. The trial has two parts: first, everyone gets a fixed dose; then, some may switch to a persona…

This early-stage study tests a new drug called STAR-0310 in 40 healthy adults to see if it is safe and how the body processes it. Participants receive either the drug or a placebo, and researchers monitor for side effects. This study does not aim to treat any disease; it is a fir…